Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity

investors.com/news/technology/viking-therapeutics-stock-weight-loss-drugs-phase-3-testing

Viking Therapeutics stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 studies could pay off.
The post Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-06-25 18:07:40.
The Entire Business World on a Single Page. Free to Use →